Skip to main content
placeholder image

C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).

Journal Article


Abstract


Publication Date


  • 2022

Citation


  • Rischin, D., Brungs, D., Day, F., Christie, H. R., Patel, V. A., Adams, G., . . . Porceddu, S. (2022). C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).. Journal of Clinical Oncology, 40(16_suppl), tps9592. doi:10.1200/jco.2022.40.16_suppl.tps9592

Web Of Science Accession Number


Start Page


  • tps9592

End Page


  • tps9592

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication


Abstract


Publication Date


  • 2022

Citation


  • Rischin, D., Brungs, D., Day, F., Christie, H. R., Patel, V. A., Adams, G., . . . Porceddu, S. (2022). C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).. Journal of Clinical Oncology, 40(16_suppl), tps9592. doi:10.1200/jco.2022.40.16_suppl.tps9592

Web Of Science Accession Number


Start Page


  • tps9592

End Page


  • tps9592

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication